What does PD-1/PD-L1 immunotherapy involve?
This treatment uses Chinese-manufactured checkpoint inhibitors, such as Tislelizumab or Sintilimab, which are administered intravenously over approximately 30 minutes every three weeks. These drugs block the PD-1/PD-L1 pathway, reactivating your immune system's T-cells to recognize and attack cancer cells. It is an outpatient procedure, so you can return home shortly after each infusion.
Preguntas relacionadas
¿Aún tienes preguntas?
Nuestro equipo está aquí para ayudar. Envíanos tu pregunta — respondemos en 24 horas.
Hacer una Pregunta